Download PDF
CC BY 4.0 · Journal of Coloproctology 2024; 44(03): e163-e170
DOI: 10.1055/s-0044-1788602
Original Article

The Predictive Value of hsa_circ_0001313 (circCCDC66) in Egyptian Rectal Cancer Patients: A New Era in Precision Medicine

Hend M. Batea 
1   Department of Medical Biochemistry, Faculty of Medicine, Alexandria University, Egypt
,
Safaa H. Mohy El-dine
1   Department of Medical Biochemistry, Faculty of Medicine, Alexandria University, Egypt
,
Eman M. Kamha
1   Department of Medical Biochemistry, Faculty of Medicine, Alexandria University, Egypt
,
Gehan M. Khedr
2   Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Alexandria University, Egypt
,
Ahmed Moaz
3   Department of Colorectal Surgery, General Surgery Unit, Faculty of Medicine, Alexandria University, Egypt
,
Doaa A. Abdelmonsif
1   Department of Medical Biochemistry, Faculty of Medicine, Alexandria University, Egypt
› Author Affiliations Funding The authors declare that they have not received funding from agencies in the public, private or nonprofit sectors to conduct the present study.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Introduction The involvement of circular RNAs (circRNAs) in cancer research has been emphasized in recent years due to evidence of their involvement in malignancy pathogenesis. Yet, the involvement of circRNAs in the resistance to cancer treatment remains to be clarified. Circular RNA 0001313 (circ_0001313) has a distinct expression in different cancers, and it is overexpressed in rectal cancer; hence, it could be a promising non-invasive stable biomarker and a therapeutic target for rectal cancer. Yet, its predictive role has not been studied in Egyptian rectal cancer patients.

Objective To study the predictive value of circulating circ_0001313 (circ_CCDCC6) in assessing the response to neoadjuvant chemoradiotherapy (nCRT) in patients with rectal cancer and its relation to radiological and pathological response.

Materials and Methods The present study included 50 patients with locally advanced rectal cancer and 20 healthy subjects as controls. The analysis of the relative circ_CCDCC6 expression was performed using the real-time quantitative polymerase chain reaction (qPCR) method.

Results The circ_CCDCC6 was found to be significantly more expressed in rectal cancer patients compared with controls (p < 0.001). Moreover, its expression level was significantly higher in nonresponders to nCRT compared with responders (p < 0.001). Furthermore, a receiver operating characteristic (ROC) curve analysis was performed to evaluate the predictive performance of circulating circ_0001313; its sensitivity in predicting the response to treatment was of 93.33%, and its specificity was of 91.43%.

Conclusion Significant up-regulation of circ_0001313 in rectal cancer suggests a potential oncogenic role, and higher expression of circ_0001313 among nonresponders suggests that it could be a predictor of the response to nCRT.

Keywords

circ_0001313 - circular RNA - rectal cancer - gene expression - response to nCRT

Authors' Contributions

All authors contributed equally to; data collection, implementation of the experiment, analysis and interpretation of results. The first draft of the manuscript was written and edited by Hend M Batea, Doaa A Abdelmonsif, Gehan M Khedr, and Ahmed Moaz. Safaa H Moy El-dine and Eman M Kamha reviewed the manuscript and approved the final version.




Publication History

Received: 21 March 2024

Accepted: 06 May 2024

Article published online:
13 August 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol 2021; 14 (10) 101174
    CrossrefPubMedGoogle Scholar
  • 2 Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin 2023; 73 (03) 233-254
    CrossrefPubMedGoogle Scholar
  • 3 Sauer R, Liersch T, Merkel S. et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012; 30 (16) 1926-1933
    CrossrefPubMedGoogle Scholar
  • 4 Fokas E, Liersch T, Fietkau R. et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol 2014; 32 (15) 1554-1562
    CrossrefPubMedGoogle Scholar
  • 5 Wei Q, Li P, Yang T. et al. The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors. J Hematol Oncol 2024; 17 (01) 1
    CrossrefPubMedGoogle Scholar
  • 6 Yan J. Precision Therapeutics: Harnessing Receptor-targeted and Dynamic DNA Nanotechnology. Finland: Abo Akademi University; 2024
    Google Scholar
  • 7 Dayde D, Tanaka I, Jain R, Tai MC, Taguchi A. Predictive and prognostic molecular biomarkers for response to neoadjuvant chemoradiation in rectal cancer. Int J Mol Sci 2017; 18 (03) 573
    CrossrefPubMedGoogle Scholar
  • 8 Vo JN, Cieslik M, Zhang Y. et al. The landscape of circular RNA in cancer. Cell 2019; 176 (04) 869-881.e13
    CrossrefPubMedGoogle Scholar
  • 9 Bahn JH, Zhang Q, Li F. et al. The landscape of microRNA, Piwi-interacting RNA, and circular RNA in human saliva. Clin Chem 2015; 61 (01) 221-230
    CrossrefPubMedGoogle Scholar
  • 10 Saleem A, Khan MU, Zahid T. et al. Biological role and regulation of circular RNA as an emerging biomarker and potential therapeutic target for cancer. Mol Biol Rep 2024; 51 (01) 296
    CrossrefPubMedGoogle Scholar
  • 11 Papatsirou M, Artemaki PI, Scorilas A, Kontos CK. The role of circular RNAs in therapy resistance of patients with solid tumors. Per Med 2020; 17 (06) 469-490
    CrossrefPubMedGoogle Scholar
  • 12 Zhang Q, Miao Y, Fu Q. et al. CircRNACCDC66 regulates cisplatin resistance in gastric cancer via the miR-618/BCL2 axis. Biochem Biophys Res Commun 2020; 526 (03) 713-720
    CrossrefPubMedGoogle Scholar
  • 13 Abdel-Hadi M, Addallah D, Amer M, Khedr G. Expression of stem cell markers Cd133 and Oct4 in rectosigmoid adenocarcinoma and their predictive significance of response to chemotherapy and\or radiotherapy. J Carcinog Mutagen 2018; 9 (325) 2
    Google Scholar
  • 14 Zhang RX, Zhou ZG, Lu SX. et al. Pim-3 as a potential predictor of chemoradiotherapy resistance in locally advanced rectal cancer patients. Sci Rep 2017; 7 (01) 16043
    CrossrefPubMedGoogle Scholar
  • 15 Lin J, Cai D, Li W. et al. Plasma circular RNA panel acts as a novel diagnostic biomarker for colorectal cancer. Clin Biochem 2019; 74: 60-68
    CrossrefPubMedGoogle Scholar
  • 16 Lu D, Ho ES, Mai H. et al. Identification of blood circular RNAs as potential biomarkers for acute ischemic stroke. Front Neurosci 2020; 14: 81
    CrossrefPubMedGoogle Scholar
  • 17 Neri E, Guidi E, Pancrazi F. et al. MRI tumor volume reduction rate vs tumor regression grade in the pre-operative re-staging of locally advanced rectal cancer after chemo-radiotherapy. Eur J Radiol 2015; 84 (12) 2438-2443
    CrossrefPubMedGoogle Scholar
  • 18 Chauvin A, Wang C-S, Geha S. et al. The response to neoadjuvant chemoradiotherapy with 5-fluorouracil in locally advanced rectal cancer patients: a predictive proteomic signature. Clin Proteomics 2018; 15: 16
    CrossrefPubMedGoogle Scholar
  • 19 Huang MY, Huang CW, Wang JY. Surgical treatment following neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Kaohsiung J Med Sci 2020; 36 (03) 152-159
    CrossrefPubMedGoogle Scholar
  • 20 Morikawa T, Kuchiba A, Qian ZR. et al. Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer. Ann Surg Oncol 2012; 19 (06) 1944-1953
    CrossrefPubMedGoogle Scholar
  • 21 Artemaki PI, Scorilas A, Kontos CK. Circular RNAs: a new piece in the colorectal cancer puzzle. Cancers (Basel) 2020; 12 (09) 2464
    CrossrefPubMedGoogle Scholar
  • 22 Mao J, Lu Y. Roles of circRNAs in the progression of colorectal cancer: novel strategies for detection and therapy. Cancer Gene Ther 2024; ••• DOI: 10.1038/s41417-024-00739-x.
    CrossrefPubMedGoogle Scholar
  • 23 Luo J, Liu H, Luan S, Li Z. Guidance of circular RNAs to proteins' behavior as binding partners. Cell Mol Life Sci 2019; 76 (21) 4233-4243
    CrossrefPubMedGoogle Scholar
  • 24 Hsiao K-Y, Lin Y-C, Gupta SK. et al. Noncoding effects of circular RNA CCDC66 promote colon cancer growth and metastasis. Cancer Res 2017; 77 (09) 2339-2350
    CrossrefPubMedGoogle Scholar
  • 25 Feng J, Li Z, Li L, Xie H, Lu Q, He X. Hypoxia–induced circCCDC66 promotes the tumorigenesis of colorectal cancer via the miR–3140/autophagy pathway. Int J Mol Med 2020; 46 (06) 1973-1982
    CrossrefPubMedGoogle Scholar
  • 26 Li J, Song Y, Wang J, Huang J. Plasma circular RNA panel acts as a novel diagnostic biomarker for colorectal cancer detection. Am J Transl Res 2020; 12 (11) 7395-7403
    PubMedGoogle Scholar
  • 27 Zhang S, Liu J, Yuan T, Liu H, Wan C, Le Y. Circular RNA 0001313 knockdown suppresses non-small cell lung cancer cell proliferation and invasion via the microRNA-452/HMGB3/ERK/MAPK Axis. Int J Gen Med 2020; 13: 1495-1507
    CrossrefPubMedGoogle Scholar
  • 28 Yang M, Wang G-Y, Qian H. et al. Circ-CCDC66 accelerates proliferation and invasion of gastric cancer via binding to miRNA-1238-3p. Eur Rev Med Pharmacol Sci 2019; 23 (10) 4164-4172
    PubMedGoogle Scholar
  • 29 Wang L, Peng X, Lu X, Wei Q, Chen M, Liu L. Inhibition of hsa_circ_0001313 (circCCDC66) induction enhances the radio-sensitivity of colon cancer cells via tumor suppressor miR-338-3p: Effects of cicr_0001313 on colon cancer radio-sensitivity. Pathol Res Pract 2019; 215 (04) 689-696
    CrossrefPubMedGoogle Scholar
  • 30 Lin Y-C, Yu Y-S, Lin H-H, Hsiao K-Y. Oxaliplatin-induced DHX9 phosphorylation promotes oncogenic circular RNA CCDC66 expression and development of chemoresistance. Cancers (Basel) 2020; 12 (03) 697
    CrossrefPubMedGoogle Scholar